For future studies investigating PSMA-targeted imaging and treatment in (soft tissue) sarcomas, it is crucial to focus on refining patient selection criteria to optimise identification of potentially eligible patients for PSMA-RLT without missing patients, while minimising unnecessary scans with no or insufficient tracer uptake and thus unnecessary patient burden and costs. The gene discussed is FOLH1; the disease is sarcoma.